Navigation Links
ResMed Inc. Announces Record Financial Results for the Quarter Ended and Six Months Ended December 31, 2010
Date:1/27/2011

ssociated with stock options, restricted stock units, and our employee stock purchase plan.  

For the six months ended December 31, 2010, revenue was $588.0 million, an increase of 13% over the six months ended December 31, 2009 (a 15% increase on a constant currency basis).  For the six months ended December 31, 2010, income from operations and net income were $136.3 million and $115.2 million, an increase of 23% and 31%, respectively, compared to the six months ended December 31, 2009.  Diluted earnings per share for the six months ended December 31, 2010 were $0.73 per diluted share, an increase of 28% compared to the six months ended December 31, 2009.

Inventory, at $214.9 million, increased by $29.2 million compared to June 30, 2010.  Accounts receivable days sales outstanding, at 67 days, decreased by 4 days compared to June 30, 2010.

Kieran T. Gallahue, President and Chief Executive Officer, commented, "In the second quarter of fiscal 2011 we continued to show strong growth year-over-year especially in Europe and the Asia-Pacific region.  Revenue in the Americas increased by 10% to $163.2 million over the prior year's quarter.  Revenue outside the Americas increased by 12% to $142.8 million over the prior year's quarter, or a 17% increase on a constant currency basis.  The growth in flow generators was mainly driven by sales of the S9™ AutoSet.  Masks sales did extremely well in all regions with the recent launches of several new masks across all categories.  Operating profit for the December quarter was $69.9 million and cash flow from operations was $68.3 million, demonstrating excellent operating performance.

"We expect the growth of all of our products to continue to benefit from the vastly under-penetrated and growing sleep-disordered breathing market.  The findings from clinical studies continue to demonstrate the importance of diagnosing and treating sleep-disordered b
'/>"/>

SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Inc. to Present at Upcoming Conferences
5. ResMed Announces Deferred Conversions in Connection With Stock Split
6. ResMed Inc. Announces Completion of Two-for-One Stock Split
7. Study Shows ResMeds New CPAP Device Increases Patient Compliance
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
9. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
10. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... and NINGBO, China , Aug. ... Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they ... of generic pharmaceuticals, primarily targeting the United ... agreement, Amerigen and Menovo will jointly develop products for ... . Menovo will be responsible for manufacturing API ...
(Date:8/27/2014)... Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" ... the following financial results for its third quarter of fiscal ... 2014: , Revenue of $1,291,378, a 13% decrease ... Net loss for the quarter of $240,156 compared to net ... year For the nine months ended June ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... from Biodel Inc. (Nasdaq: BIOD ) reported ... basal insulin and stabilized glucagon development programs in poster ... Technology Meeting in Bethesda, MD.   Dr. ... double-blind, randomized crossover trial in 13 subjects with type ...
... (NYSE Amex: NBS ) ("NeoStem" or the ... revenues, global research and development capabilities and operations in ... adult stem cells, and China pharmaceuticals, is today providing ... Third Quarter Results Revenues for the nine ...
Cached Medicine Technology:Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 2Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 3Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 4Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 5NeoStem Provides Third Quarter Update 2NeoStem Provides Third Quarter Update 3
(Date:8/27/2014)... The genome we inherited from our parents shapes many ... genome we have an epigenome that is set during ... and environmental exposuresand perhaps by those of our parents ... on our DNA and supporting proteins that determine whether ... are deeply responsible for our own health, but also ...
(Date:8/27/2014)... growth in health care spending for commercially insured individuals ... services, rather than increased use, according to a new ... Health Policy & Clinical Practice, published in the August ... . , There is increasing concern that consolidation in ... faced by payers and, ultimately, consumers," said Carrie Colla, ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... leading pediatric practice, Hoboken Pediatrics has joined our ... Dr. Andrzej Klos, Dr. Piotr Oko, Dr. Yanina ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ...
(Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
(Date:8/27/2014)... Silver Spring and Germantown, Md., and Denver (PRWEB) August ... healthcare real estate developer , has broken ground ... on the new Holy Cross Health hospital campus in ... of Bethesda, Md. Germantown is the third most populous ... medical office building on the Holy Cross Germantown Hospital ...
Breaking Medicine News(10 mins):Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:Tracking spending among the commercially insured 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 4
... Since mephedrone was made illegal in the UK in 2010, the ... degraded, which in turn may have reduced use of the drug. ... continued to use mephedrone after it became illegal would switch to ... by their friends or on the Internet. They would be ...
... health records (EHRs) are rapidly becoming part of the ... of care. In the first large study of its ... Nursing determined that nurses working with EHRs consistently reported ... for patients than nurses working in hospitals without this ...
... , TUESDAY, Jan. 17 (HealthDay News) -- With the Alzheimer,s ... ages, a panel of experts is meeting for two days ... fast emerging as one of the nation,s biggest -- and ... is to improve diagnosis, buttress support and training programs for ...
... drug called regorafenib slowed the progression of tumors and lengthened ... an international phase III clinical trial found. The findings were ... American Society of Clinical Oncology in San Francisco by ... principal investigator of the trial in the United States. ...
... are performed on all newborns born in the U.S. ... are not apparent at birth. These newborn screening programs ... early and improve outcomes in potentially devastating conditions. ... the data collection linked to newborn screening results, aiming ...
... Jan. 16, 2012 Listen up, pedestrians wearing headphones. ... Many probably can,t, especially young adult males. Serious ... in six years, according to new research from the University ... Medical Center in Baltimore. In many cases, the cars ...
Cached Medicine News:Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 3Health News:Drug improves survival of colorectal cancer patients, trial results show 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 3Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 2Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: